Novo Nordisk bets on Wegovy pill to win weight loss battle beyond U.S.

Novo Nordisk has instructed CNBC how it’s getting ready to go “all in” on launching its Wegovy tablet outdoors the U.S, because the battle for dominance of the weight-loss market goes international.

“Once we launch, we’ll go all in,” Novo’s Govt Vice President for Worldwide Operations, Emil Kongshøj Larsen, instructed CNBC in an interview on Tuesday. “It is a main alternative.”

Novo introduced final week that it expects to start out the primary launches outdoors of the U.S. later this yr, pending approvals, after the tablet continues to impress with unparalleled U.S. uptake.

The U.S. market accounts for greater than half of the gross sales of each Novo and its chief rival Eli Lilly. However the corporations are actually trying more and more to broaden the marketplace for weight-loss medication which have revolutionized the pharmaceutical area in recent times.

Larsen would not title particular nations the place Novo may launch the Wegovy tablet first, saying the drugmaker will “go based on potential,” highlighting components resembling affected person curiosity in weight problems therapy, how well-trained medical doctors are, and the existence of potential telehealth companions.

Larsen stated that telehealth had been a method of broadening entry to sufferers, saying that, in Germany, “it has been sluggish for some time, and hastily, telehealth helps sufferers get entry to therapy in a approach that could be very handy and appreciated.”

Whereas Eli Lilly expects gross sales to develop 28% on the midpoint of its steering this yr, Novo has forecast a drastic decline in gross sales.

Novo hiked its steering barely final week, however nonetheless expects earnings and gross sales to say no between 4% and 12% in 2026, damage by decrease costs within the U.S. and generic competitors in markets together with India, Canada, Brazil, and China.

That is regardless of Novo gaining an early lead within the oral weight reduction medication with the U.S. launch of the Wegovy tablet in January. Final week, Novo stated whole prescriptions had reached greater than 2 million, as gross sales massively beat expectations in its first quarter regardless of its cheaper price level. 

“We can not have a greater pre-launch in a world that is turn out to be very small in terms of social media, digital, sentiment, and many others.,” Larsen stated, referring to the united stateslaunch. “It is also very thrilling for our injectable franchise, as a result of it is energizing the entire Wegovy model,” he added.

Nordea analysts stated in a observe to purchasers that Wegovy is turning into the primary family weight reduction model within the U.S., based mostly on Google Developments knowledge, which aligns with prescription tendencies.

In the meantime, Lilly stated on April 30 that greater than 20,000 folks had began taking the rival tablet Foundayo because it launched earlier that month.

In keeping with analysts carefully monitoring weekly U.S. prescription knowledge, Foundayo has recorded far fewer prescriptions in contrast with the Wegovy tablet within the comparable interval, based on IQVIA knowledge, which does not seize all prescriptions, however provides market watchers a sign of demand. 

Lilly CEO David Ricks instructed CNBC late final month that establishing Foundayo as a model would “take a while.” Foundayo makes use of a unique lively ingredient than Lilly’s blockbuster injectables Mounjaro and Zepbound, whereas Novo’s Wegovy tablet is basically an extension of the corporate’s injectable equivalents. 

“Our ramp goes to be slightly completely different, as a result of it is a new model, a brand new molecule,” Ricks stated. “That is going to play out over quarters, not days… ask folks to take a beat and allow us to execute.”

Barclays analyst Emily Area famous final week that oral Wegovy and Foundayo are going for various affected person segments, with the previous having “injectable-like efficacy” and the latter maybe being considered as extra of a “starter” GLP-1.

Each Ricks and Novo CEO Mike Doustdar say the drugs are increasing the market, relatively than considerably capitalizing on demand for the injectables.

The tablet format is interesting to many sufferers, and “we imagine [it] will probably be replicated additionally in our a part of the world,” Larsen instructed CNBC, referring to ex-U.S. markets.

Larsen stated Wegovy tablet’s “superior efficacy” meant he wasn’t fearful if launched after the competitors in sure markets.

Research have urged that the tablet ends in extra pronounced weight reduction than Foundayo and has sure cardiovascular advantages, however thus far, no medical trial has straight in contrast the 2 medication.

Larsen stated that Novo expects a “very robust uptake” of the Wegovy tablet internationally however not essentially with the identical form of curve as within the U.S.

He stated the U.S. is not a very good comparability with different nations as a result of uptake will rely upon the relative worth distinction in comparison with injectable variations.

“We’re not detailing our pricing strategy thus far, however you might say within the U.S., there is a incredible product, however there’s additionally one other worth level in comparison with injectable remedies.”

He predicted worldwide gross sales might have “an optic curve that is possibly barely extra bent than the U.S. curve.”

Sydbank analyst Soren Hansen instructed CNBC on Wednesday that Wegovy’s launch outdoors the U.S. may very well be “extra selective” and can replicate the corporate’s “capacity to satisfy the demand.” He highlighted massive European markets such because the U.Okay. and Germany as seemingly early markets for launch, in addition to Novo’s residence nation, Denmark. 

Larsen instructed CNBC that Novo noticed most development for weight problems GLP-1s coming from cash-paying clients, versus these lined by nationwide healthcare methods or insurers.

“Even in socialized healthcare methods just like the Danish, 99% of all sufferers are paying out of pocket. We would not have imagined that just a few years again, after we began with weight problems care,” he added.

In late April, Lilly CEO Ricks instructed CNBC that worldwide launches gave the corporate a “massive runway.”

“There are a billion folks on the planet who may benefit from these drugs… proper now we’re reaching about 20 million, he stated.

Lilly’s first-quarter income outdoors of the U.S. jumped 81% to $7.7 billion, fuelled by a 95% surge in quantity. Income within the U.S. climbed 43% within the quarter to $12.1 billion. “It seems folks prefer to drop some pounds all around the globe,” Ricks stated.

President Donald Trump’s so-called most-favored-nation drug pricing coverage, whereby costs within the U.S. market are tied to costs in a set of reference nations, has difficult drug launches for a lot of pharmaceutical corporations.

Novo’s Larsen stated that how European nations handle pricing for medicines would not have an effect on out-of-pocket launches.

“It is, in fact, important that the European governments additionally settle for that paying for high quality innovation that adjustments public well being, as a result of in any other case investments and medical trials, and many others, will hold transferring in the direction of the U.S. or China, as we see in the meanwhile,” Larsen stated.